The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-1-(3-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one ID: ALA5289003
Max Phase: Preclinical
Molecular Formula: C22H20N6O
Molecular Weight: 384.44
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: C=CC(=O)N1CC[C@H](n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1
Standard InChI: InChI=1S/C22H20N6O/c1-2-19(29)27-8-7-16(11-27)28-12-17(20-21(23)25-13-26-22(20)28)15-9-14-5-3-4-6-18(14)24-10-15/h2-6,9-10,12-13,16H,1,7-8,11H2,(H2,23,25,26)/t16-/m0/s1
Standard InChI Key: IQJPWAAWPFBLPZ-INIZCTEOSA-N
Molfile:
RDKit 2D
29 33 0 0 0 0 0 0 0 0999 V2000
1.2563 -3.0910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0094 -2.7540 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6791 -3.2367 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1689 -3.9147 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.5865 -2.6084 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.5824 -1.7805 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2038 -1.5268 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6864 -2.1966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1996 -2.8622 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6791 -0.4950 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9594 -0.9069 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.2480 -0.4909 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2522 0.3369 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9677 0.7488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6791 0.3327 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.4617 -0.7446 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.4659 0.5948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0207 -0.0748 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5117 2.7790 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.7655 1.9927 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2121 1.3811 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5990 1.5559 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8486 2.3421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6599 2.5169 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9137 3.3032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3562 3.9147 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5490 3.7442 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2953 2.9537 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9677 1.5725 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
1 4 2 0
1 5 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 1 0
5 9 1 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 2 0
14 15 1 0
10 15 2 0
12 16 1 0
7 16 1 6
13 17 1 0
17 18 2 0
16 18 1 0
19 20 2 0
20 21 1 0
17 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 27 1 0
27 28 2 0
19 28 1 0
23 28 1 0
14 29 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 384.44Molecular Weight (Monoisotopic): 384.1699AlogP: 3.19#Rotatable Bonds: 3Polar Surface Area: 89.93Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 6.54CX LogP: 2.26CX LogD: 2.20Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.55Np Likeness Score: -0.73
References 1. Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T.. (2023) Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use., 14 (4): [PMID:37077386 ] [10.1021/acsmedchemlett.3c00006 ]